Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy

Annales d'Endocrinologie

Volumn 72, Issue 3, 2011, Pages 244-246

  Oriot, P ^a   Hermans, M P ^b   Selvais, P ^a   Buysschaert, M ^b   de la Tribonniere X ^c  

^a Mouscron Hospital   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c UNIV LILLE   (France)

Author keywords

Antiretroviral therapy; Diabetes; Efficacy; HIV; Incretin mimetic drug

Indexed keywords

EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EXENDIN 4; INSULIN GLARGINE; METFORMIN; REPAGLINIDE;

ADULT; ARTICLE; B LYMPHOCYTE; CASE REPORT; DRUG RESPONSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN SENSITIVITY; LYMPHOCYTE FUNCTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SIDE EFFECT; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WEIGHT GAIN; WEIGHT REDUCTION;

ADIPOSE TISSUE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARBAMATES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; METFORMIN; MIDDLE AGED; PEPTIDES; PIPERIDINES; VENOMS; WAIST CIRCUMFERENCE; WEIGHT LOSS;

EID: 79959365697     PISSN: 00034266     EISSN: 00034266     Source Type: Journal    
DOI: 10.1016/j.ando.2011.04.003     Document Type: Article

References (11)

1. Buysschaert M., Preumont V., Oriot P., et al. One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. Diabetes Metab 2010, 36:381-388.
2. De Wit S., Sabin C.A., Weber R., Worm S.W., Reiss P., Cazanave C., et al. Data collection on adverse events of anti-HIV drugs (DAD) study. Incidence and risk factors for new-onset diabetes in HIV-infected patients. Diabetes Care 2008, 31:1224-1229.
3. Capeau J., Caron M., Vigouroux C., Cervera P., Kim M., Maachi M., et al. Les lipodystrophies secondaires aux traitements antirétroviraux de l'infection par le VIH. Med Sci 2006, 22:531-536.
4. Lagathu C., Eustace B., Prot M., et al. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther 2007, 12:489-500.
5. Kim M.J., Leclercq P., Lanoye E., et al. A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study. Antivir Ther 2007, 12:1273-1283.
6. Lemoine M., Barbu V., Girard P.M., et al. Altered hepatic expression of SREBP-1 and PPARγ is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. AIDS 2006, 20:387-395.
7. Heine R.J., Van Gaal L.F., Johns D., Mihm M.J., Widel M.H., Brodows R.G. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005, 143:559-569.
8. Gérard Y., Viget N., Yazdanpanah Y., Ajana F., de La Tribonnière X., Bocket L., et al. Hyperlactataemia during antiretroviral therapy: incidences, clinical data and treatment. Therapie 2003, 58:153-158.
9. Yeni P, et al. Prise en charge médicale des personnes infectées par le VIH en France. Recommandations du groupe d'experts - Rapport 2010. Ministère de la Santé et des Sports.
10. Preumont V., Hermans M.P., Brichard S., Buysschaert M. Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity. Diabetes Metab 2010, 36:293-298.
11. Sheth S.H., Larson R.J. The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. BMC Infect Dis 2010, 10:183.